Who should get a Chlamydia test and what is the standard treatment for a positive result in individuals between 15 and 35 years old who are sexually active?

Chlamydia Screening and Treatment for Sexually Active Individuals Aged 15-35

Who Should Be Screened

All sexually active women aged 24 years or younger should receive annual chlamydia screening, regardless of symptoms or perceived risk factors. 1, 2

Women Aged 15-24 Years

• Universal annual screening is recommended for all sexually active women in this age group 1, 2
• This population has the highest infection rates, with 4.7% overall prevalence and 13.5% among non-Hispanic Black females 3
• Up to 70% of chlamydial infections in women are asymptomatic, making screening essential to prevent complications including pelvic inflammatory disease, infertility, and ectopic pregnancy 4, 5

Women Aged 25-35 Years

• Screen annually if any of the following risk factors are present: 1, 6
  • New sex partner
  • Multiple sex partners
  • Partner with concurrent partners or unknown sexual history
  • Inconsistent condom use
  • History of previous STIs
  • Commercial sex work
  • Illicit drug use
  • Partner who uses drugs or has multiple partners
• Do not screen women over 24 years without these risk factors, as potential harms may outweigh benefits in low-prevalence populations 6, 2

Men Aged 15-35 Years

• Routine screening is not recommended for heterosexual men in general populations 1, 2
• Consider screening in high-prevalence settings: jail/juvenile detention facilities, STD clinics, adolescent clinics, high school clinics, or national job training programs 1
• Annual screening is recommended for men who have sex with men, with urethral testing for insertive intercourse and rectal testing for receptive anal intercourse 1
• Screen every 3-6 months for men who have sex with men with high-risk behaviors (multiple/anonymous partners, substance use during sex) 1

Pregnant Women

• Screen all pregnant women at the first prenatal visit, regardless of age 1
• Retest in the third trimester if initial test was positive or if continued risk factors are present 1

Testing Methodology

Specimen Collection

• Women: Vaginal swab (preferred, can be self-collected) or first-catch urine 7, 8, 6
• Men: First-catch urine or urethral swab 7, 8
• Men who have sex with men: Test all exposure sites—urethral, rectal, and pharyngeal specimens based on sexual practices 1, 7, 8

Test Type

• Nucleic acid amplification tests (NAATs) are the preferred method due to superior sensitivity (89-100% across anatomical sites) and specificity 7, 8, 6, 9
• The same specimen can test for both chlamydia and gonorrhea simultaneously 8, 6

Standard Treatment for Positive Results

First-Line Treatment Options

Azithromycin 1 gram orally as a single dose OR doxycycline 100 mg orally twice daily for 7 days 5

Alternative Regimens (When First-Line Contraindicated)

• Erythromycin 500 mg orally four times daily for 7 days 10, 5
• For pregnant women who cannot tolerate the standard erythromycin regimen: 500 mg orally every 12 hours or 250 mg four times daily for at least 14 days 10

Critical Post-Treatment Management

Retest at 3 months after treatment is mandatory, regardless of whether the patient believes their partner was treated. 1, 7, 8

• Reinfection rates are 25-40% within 3-6 months after treatment 8
• This is a test-of-reinfection, not test-of-cure 1

Partner Management

• All sexual partners from the preceding 60 days must be evaluated and treated 7, 8
• Partners should receive the same treatment regimen even if asymptomatic 7
• Expedited partner therapy may be appropriate depending on local regulations 7
• Patients should abstain from sexual activity for 7 days after completing treatment 7

Common Pitfalls to Avoid

• Do not rely on symptoms alone—most chlamydial infections are asymptomatic, particularly in women 3, 4, 5
• Do not skip retesting at 3 months after positive results, even if the partner was reportedly treated—reinfection rates remain high 1, 7, 8
• Do not accept patient self-report of "always using condoms" as sufficient reassurance to skip screening in high-risk populations 7
• Do not test only genital sites in men who have sex with men—pharyngeal and rectal infections are frequently missed if exposure-specific sites are not tested 1, 7
• Do not screen low-risk women over 24 years without specific risk factors, as this may cause more harm than benefit 6, 2